This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AF55 Publication ID: Fall 2004 
Title: ●Requirements for Human and Animal Medical Products Manufactured From, Processed With, or Otherwise Containing Material From Cattle 
Abstract: This is a companion rulemaking to FDAs rule entitled "Use of Materials Derived From Cattle in Human and Animal Medical Products," to be published in the same issue of the Federal Register. The rule would propose recordkeeping requirements for human and animal medical products that contain cattle material. Manufacturers and sponsors of such products would have to establish and maintain records to demonstrate that prohibited materials were not used in their manufacture. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: First time published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 116; 21 CFR 226.60; 21 CFR 300.200; 21 CFR 500; 21 CFR 600.16; 21 CFR 895; 21 CFR 1271.465; 21 CFR 1271.470 
Legal Authority: Not Yet Determined 
Legal Deadline:  None

Statement of Need: FDA is proposing recordkeeping requirements because records documenting the absence of prohibited cattle materials are needed by manufacturers and processors of human medical products and animal drugs that contain or are manufactured with cattle material to ensure that these products do not contain prohibited cattle materials. Prohibited cattle materials are materials that scientific studies have demonstrated are highly likely to contain the BSE agent in cattle infected with the disease. Scientists believe that the human disease variant Creutzfeldt-Jakob disease (vCJD) is likely caused by the consumption of products contaminated with the agent that causes BSE. FDA is proposing additional restrictions for higher risk human medical products and for ruminant drugs to address the greater disease risk posed by these products should they contain any infectious material from a BSE-positive animal.

Summary of the Legal Basis: Undetermined.

Alternatives: Alternatives were not specifically considered in the proposed rule with regard to recordkeeping requirements because it was a companion rulemaking to the interim final rule prohibiting the use of certain cattle material in human medical products and animal drugs. Recordkeeping alternatives were considered in the interim final rule. Those same alternatives, plus any new ones presented in comments, will be considered for the final rule. There were several alternatives considered to the proposed additional restrictions. These same alternatives, plus any new ones presented in comments, will be considered for the final. No additional restrictions. Prohibit the use in higher risk human medical products of listed neural tissues from cattle 12 months and older and all cattle material from countries listed by APHIS as having unacceptable risk or incidence of BSE, and prohibit the use in ruminant drugs of those materials that are prohibited in ruminant feed.

Anticipated Costs and Benefits: FDA believes this rule reflects current practices of most affected manufacturers. The costs of this rule are the costs to industry of assuring that prohibited materials are not used in the manufacture of medical products and of conforming with additional restrictions on the use of cattle material in certain medical products (implantable, etc.). In addition, affected manufacturers will incur costs associated with establishing and maintaining records to demonstrate compliance. By reducing exposure to potentially infective materials, this rule will provide an additional safeguard against a case of vCJD occurring in humans if cattle infected with BSE are used in the manufacture or processing of medical products.

Risks: The benefits of finalizing the proposed rule with respect to its recordkeeping requirements are derived from the benefits of the interim final rule, which are the value of the public and animal health benefits. The benefits of finalizing the proposed rule with respect to its additional requirements are also the value of the public and animal health benefits. The public and animal health benefit is the reduction in the risk of the human or animal illness associated with exposure to the agent that causes BSE.

Timetable:
Action Date FR Cite
NPRM  02/00/2005   
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: Undetermined 
Included in the Regulatory Plan: Yes 
Agency Contact:
Eric Flamm
Senior Policy Advisor, Office of Policy
Department of Health and Human Services
Food and Drug Administration
Office of the Commissioner, WO1, Room 4315B, 10903 New Hampshire Ave.,
Silver Spring, MD 20993
Phone:301 796-4726
Fax:301 847-3541
Email: eric.flamm@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us